Testing Revenue was Veracyte’s largest product and service line in fiscal 2025, bringing in $493.15M of $517.15M (95%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Testing Revenue | $250.54M | $326.54M | $418.96M | $493.15M | |||||
| Testing | — | — | — | — | |||||
| Biopharmaceutical Revenue | $26.34M | $13.87M | $7.15M | $6.54M | |||||
| Product Revenue | $12.63M | $15.59M | $13.65M | $14.33M | |||||
| Provision Of Data | — | — | — | — | |||||
| Contract Manufacturing & Testing | $7.02M | $5.05M | $6.00M | $3.13M | |||||
| Collaboration Milestones | — | — | — | — | |||||
| Development Services | — | — | — | — | |||||
| Biopharmaceutical | — | — | — | — | |||||
| Total | $296.54M | $361.05M | $445.76M | $517.15M |
Veracyte brought in $517.15M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 16.0% from $445.76M in fiscal 2024. Testing Revenue was the largest at $493.15M (95.4%), ahead of Product Revenue at $14.33M (2.8%) and Biopharmaceutical Revenue at $6.54M (1.3%). The remaining line, Contract Manufacturing & Testing, brought in $3.13M.
Compared with fiscal 2024, Testing Revenue grew 17.7% to $493.15M and Product Revenue grew 5.0% to $14.33M. From fiscal 2022 to 2025, combined revenue from these lines grew from $296.54M to $517.15M, a compound annual growth rate of 20.4%. Testing Revenue's share of the total rose from 84.5% to 95.4%.
United States was Veracyte’s largest region in fiscal 2025, bringing in $496.60M of $517.15M (96%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| United States | $262.92M | $334.53M | $423.54M | $496.60M | ||||
| International | $33.61M | $26.53M | $22.23M | $20.55M | ||||
| Total | $296.54M | $361.05M | $445.76M | $517.15M |
Veracyte brought in $517.15M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 16.0% from $445.76M in fiscal 2024. United States was the largest at $496.60M (96.0%), ahead of International at $20.55M (4.0%).
Compared with fiscal 2024, United States grew 17.3% to $496.60M, while International fell 7.6% to $20.55M. From fiscal 2022 to 2025, combined revenue from these regions grew from $296.54M to $517.15M, a compound annual growth rate of 20.4%. United States' share of the total rose from 88.7% to 96.0%.
Veracyte (VCYT) reports its revenue by product and service and by geography. In fiscal 2025, Testing Revenue was its largest product and service line, bringing in $493.15M (95.4% of the total), followed by Product Revenue at $14.33M (2.8%).
Testing Revenue was Veracyte's largest product and service line in fiscal 2025, bringing in $493.15M, or 95.4% of the $517.15M total across its four product and service lines.
United States was Veracyte's largest region in fiscal 2025, bringing in $496.60M, or 96.0% of the $517.15M total across its two regions.
Testing Revenue grew faster than Product Revenue in fiscal 2025, up 17.7% from $418.96M to $493.15M. Product Revenue grew 5.0% to $14.33M.
Every figure comes from Veracyte's annual financial filings, as reported. Each line keeps the name Veracyte gives it, and years follow its fiscal calendar.
Veracyte's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.